Lung Cancer:中国社区人群低剂量CT肺癌筛查

2018-02-13 Wrangx 肿瘤资讯

上海胸科医院韩宝惠教授于《lung cancer》发表了一篇关于中国社区人群低剂量CT肺癌筛查的研究文章。研究目的是评价低剂量CT对吸烟和不吸烟中国社区人群早期肺癌高危生存的筛查能力。

上海胸科医院韩宝惠教授于《lung cancer》发表了一篇关于中国社区人群低剂量CT肺癌筛查的研究文章。研究目的是评价低剂量CT对吸烟和不吸烟中国社区人群早期肺癌高危生存的筛查能力。自2013年至2014年,具有高危因素患者随机分为筛查组或对照组,不能确定结节或肿物最大径≥4mm判断为CT筛查阳性。入组人群6717例(低剂量CT组3550例,对照组3167例),3512例(98.9%)行低剂量CT扫描,3145例(99.3%) 接受问卷调查。筛查阳性率为22.9%(804/3512)。随访2年,低剂量CT发现肺癌51例(1.5%),而对照组10例(0.3%),早期肺癌分别占94.1%对比 20%。研究结论为与常规医疗对比,低剂量CT可增加74.1%早期肺癌发现率。

原始出处:

WenjiaYang,et al.Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.Lung Cancer.Volume 117, March 2018, Pages 20-26

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=290077, encodeId=01932900e7ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Feb 23 02:15:41 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395750, encodeId=52d51395e50f8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423969, encodeId=5d94142396969, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480484, encodeId=f3071480484a1, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=)]
    2018-02-23 秀红

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=290077, encodeId=01932900e7ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Feb 23 02:15:41 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395750, encodeId=52d51395e50f8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423969, encodeId=5d94142396969, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480484, encodeId=f3071480484a1, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=290077, encodeId=01932900e7ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Feb 23 02:15:41 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395750, encodeId=52d51395e50f8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423969, encodeId=5d94142396969, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480484, encodeId=f3071480484a1, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=290077, encodeId=01932900e7ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Feb 23 02:15:41 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395750, encodeId=52d51395e50f8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423969, encodeId=5d94142396969, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480484, encodeId=f3071480484a1, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Feb 15 02:03:00 CST 2018, time=2018-02-15, status=1, ipAttribution=)]

相关资讯

ASCO 2014:全国低剂量CT(LDCT)肺癌筛查研究

摘要号:#6501题目:医疗保险Medicare项目中的低剂量CT(LDCT)肺癌筛查:反映出的临床、资源和预算影响背景:基于国家肺癌筛查试验(NLST)中获得的证据,美国预防服务任务组(USPSTF)近期推荐对目前吸烟者既往吸烟30包/年或过去15年内戒烟的55-80岁患者,每年进行LDCT肺癌筛查。根据平价医疗法案条款,Medicare将给付筛查费用。我们对该政策的临床、资源和预算影响做一调查

NEJM:低剂量CT筛查对于肺癌高危人群具有成本效益

New England Journal of Medicine 11月5日发表的一项分析显示,对于肺癌高危人群,CT筛查具有成本效益。研究者分析了美国国家肺筛查试验(NLST)的数据,估算出低剂量CT筛查肺癌的成本大约为每获得一个质量调整生命年(QALY)81,000美元,不过在具体分析不同的亚组时这一数据相差很大(N. Engl. J Med. 2014;371:1793-802 [doi:10

Ann Rheum Dis:与常规影像比较,低剂量CT可以检测强直性脊柱炎更多骨形成进展

与CR相比,ldCT覆盖AS患者的整个脊柱,并可以发现更多的新生和进展韧带骨赘形成。

Ann Intern Med:低剂量CT扫描采用Lung-RADS标准识别肺癌无优势

低剂量CT(LDCT)扫描适用于肺癌的筛查已经被广受推荐,这主要源于美国国立胸部摄像研究(the National Lung Screening Trial,NLST)证据所支持。最近美国放射学会(American College of Radiology)发布了Lung-RADS标准(Lung-RADS是一种专门针对LDCT的肺癌扫描结果的分级和分类工具)。 为评估Lung-RADS相对于NLS